India and the UK will soon establish a framework for fruitful cooperation and exchange of information in the field of medical products’ regulation, facilitating the exchange of information and cooperation in various fields related to the sector and control unlicensed exports and imports of medical products.
The move comes after the Union Cabinet, chaired by Prime Minister Narendra Modi, on Wednesday approved the signing of a Memorandum of Understanding (MoU) between India and the UK on cooperation in medical products’ regulation.
Follow NewsGram on Twitter to stay updated about the World news.
The pact will be signed between India’s Central Drugs Standard Control Organisation (CDSCO) and the UK Medicines and Healthcare Products Regulatory Agency (UK MHRA).
The MoU will help establish a framework for fruitful cooperation and exchange of information between the CDSCO and the UK MHRA in matters relating to medical products’ regulation in line with their international responsibilities.
Follow NewsGram on Instagram to keep yourself updated.
The main areas of cooperation between the two regulatory authorities include the exchange of safety information, and pharmacovigilance, where there is a particular safety concern related to the other party, which includes safety concerns relating to medicines and medical devices.
The pact will help in participation in scientific and practical conferences, symposia, seminars organized by India and the UK.
It will facilitate the exchange of information and cooperation on good laboratory practices (GLP), good clinical practices (GCP), good manufacturing practices (GMP), good distribution practices (GDP), and good pharmacovigilance practices (GPvP) between the two countries.
It will also help in capacity building in mutually agreed areas.
Follow NewsGram on LinkedIn to know what’s happening around the world.
The pact will help in promoting an understanding between the parties of each other’s regulatory framework and facilitate future regulatory strengthening initiatives for both the parties.
The MoU will support the exchange of information on laws and regulations regarding medicines and medical devices.
Both countries will be able to share information and support efforts to control unlicensed exports and imports. They can also coordinate at the international fora.
The pact would also facilitate a better understanding of the regulatory aspects between the two sides and could help in increased cooperation in the field of medical product regulation and better coordination in the international fora. (IANS)